A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
198estimated
Sites
13
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2014-03-10 | actual | When the study began enrolling |
| Primary completion | 2021-03-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2014-02-06 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Neoplasms
Interventions
- Drug: LY2835219 — also filed as Abemaciclib
- Drug: Letrozole
- Drug: Anastrozole
- Drug: Tamoxifen
- Drug: Exemestane
- Drug: Everolimus
- Drug: Trastuzumab
- Drug: LY3023414
- Drug: Fulvestrant
- Drug: Pertuzumab
- Drug: Loperamide
- Drug: Endocrine therapy
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with One or More Drug-Related Adverse Events
measured Baseline through study completion (estimated as 12 months)
Publications
- PMID 35223458 — linked by the registry
- PMID 24919854 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed